Copyright
©The Author(s) 2018.
World J Gastroenterol. May 14, 2018; 24(18): 1925-1941
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.1925
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.1925
Table 1 Tyrosine kinase inhibitor election based on genes mutations
| Gene | Mutation | TKI. Dose |
| KIT | Exon 11 | Imatinib-Mesylate 400 mg/d |
| Exon 13 | ||
| Exon 17 | ||
| Exon 9 | Imatinib-Mesylate 800 mg/d | |
| PDGFRA | Exon 18. D842V mutation | Sunitinib 50 mg/d |
| Regorafenib 160 mg/d | ||
| Exon 12 | Imatinib-Mesylate 400 mg/d | |
| Exon 14 | ||
| Exon 18. Non D842V mutations. | ||
| Wild-type | Sunitinib 50 mg/d | |
| Regorafenib 160 mg/d |
- Citation: Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J. Gastrointestinal stromal tumors: A multidisciplinary challenge. World J Gastroenterol 2018; 24(18): 1925-1941
- URL: https://www.wjgnet.com/1007-9327/full/v24/i18/1925.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i18.1925